TMS SAFETY

MOUHSIN SHAFI, MD/PHD BERENSON-ALLEN CENTER FOR NONINVASIVE BRAIN STIMULATION BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL

0 520 500

OVERVIEW

TMS is generally a safe and well-tolerated procedure

- Seizures, often considered the most serious risk, are very rare!
- Side effects are generally quite manageable
- BUT investigators should be prepared to manage the common and uncommon side effects
- Safety considerations in special populations and with devices

KEY PAPER



Clinical Neurophysiology 132 (2021) 269-306

Contents lists available at ScienceDirect

Clinical Neurophysiology

journal homepage: www.elsevier.com/locate/clinph

Review

Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines

Simone Rossi^{a,*}, Andrea Antal^{b,c}, Sven Bestmann^d, Marom Bikson^e, Carmen Brewer^f, Jürgen Brockmöller^g, Linda L. Carpenter^h, Massimo Cincottaⁱ, Robert Chen^j, Jeff D. Daskalakis^k, Vincenzo Di Lazzaro¹, Michael D. Fox^{m,n,o}, Mark S. George^p, Donald Gilbert^q, Vasilios K. Kimiskidis^r, Giacomo Koch^s, Risto J. Ilmoniemi^t, Jean Pascal Lefaucheur^{u,v}, Letizia Leocani^w, Sarah H. Lisanby^{x,y,2}, Carlo Miniussi^z, Frank Padberg^{aa}, Alvaro Pascual-Leone^{ab,ac,ad}, Walter Paulus^b, Angel V. Peterchev^{ae}, Angelo Quartarone^{af}, Alexander Rotenberg^{ag}, John Rothwell^d, Paolo M. Rossini^{ah}, Emiliano Santarnecchi^m, Mouhsin M. Shafi^m, Hartwig R. Siebner^{ai,aj,ak}, Yoshikatzu Ugawa^{al}, Eric M. Wassermann^{am,2}, Abraham Zangen^{an}, Ulf Ziemann^{ao}, Mark Hallett^{ap,2,*}, The basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020¹



NOT JUST ADVERSE EFFECTS

Contents

1.	Introd	duction
2.		TMS devices and methods
	2.1.	Risk analysis and management
	2.2.	Technical safety
	2.3.	Stimulation dose safety
	2.4.	Experimental/animal models
	2.5.	Manufacturer vs user responsibilities
		Manufacturer responsibilities
		User responsibilities
	2.6.	Brief review of new devices and paradigms
		2.6.1. New pulse generators and stimulus waveforms
		2.6.2. New pulse sequences
		2.6.3. New coils
		2.6.4. Other paradigms of stimulation (Low field magnetic stimulation; transcranial static magnetic stimulation)
		2.6.5. Role of neuroimaging in improving TMS safety
		2.6.6. Image-guided frameless navigation and robots for improving TMS safety: an emerging issue
3.	Safety	y in combination with other devices
	3.1.	MRI environment
	3.2.	Implanted or non-removable intracranial metal or devices

BUT THOSE TOO!

4.

6.

9.

	3.2.1. Heating	
	3.2.2. Forces and magnetization	279
	3.2.3. Induced electrode current	
	3.2.4. Malfunction or damage of electronic implants	
	3.2.5. TMS in patients with implanted stimulating/recording electrodes	
	3.2.6. Conclusions and recommendations	281
3.3.	tDCS/tACS/tRNS	281
3.4.	Drugs	282
Adve	rse effects	282
4.1.	Seizures	
	4.1.1. Risk factors for TMS-provoked seizures	282
	Neuropsychiatric disease	283
	General factors relevant to TMS-provoked seizure	
	Medical factors relevant to TMS-provoked seizure	283
	4.1.2. The rate of seizures caused by TMS	
4.2.	Hearing	
4.3.	TMS safety on cognition	285
	4.3.1. Cognitive TMS effects in experimental studies	285
	4.3.2. Cognitive TMS effects in clinical studies	
4.4.	Special issues for children and pregnancy.	
	Hearing in pediatrics.	
	TMS in pregnancy.	
Magr	etic seizure therapy	
	effects in specific patient populations	
6.1.	Neurology and rehabilitation .	
6.2.	Alzhemer's disease and new multi-site stimulation paradigms	
6.3.	Psychiatry	
	te of safety tables	
7.1.	Conventional rTMS: low and high frequency	
7.2.	Patterned rTMS: Quadripulse stimulation (QPS)	
7.3.	Patterned rTMS: theta burst stimulation (TBS).	
7.4.	Paired associative stimulation (PAS) protocols	
	ing of operators	
.8.1.	Requirements for TMS users (summary of IFCN training guidelines)	
8.2.	Safety for operators.	
	latory issues and ethics (with a note on neuroenhancement)	
9.1.	TMS in research or clinical setting	
5.1.	9.1.1. Basic, physiological, non-therapeutic research	
	9.1.2. Therapeutic research	
	9.1.3. Therapeutic clinical application.	
9.2.	Steps to mitigate risk	
9.2.	9.2.1. TMS in vulnerable populations	
9.3.	Recommendations on minimum safety precautions of different use and settings of TMS	295
9.4.	Limitations of current safety data	295
9.5.	Registration, standardized documentation and reporting.	
9.5. 9.6.	A note on neuroenhancement	
	aration of Competing Interest	
	owledgments	
Kefer	ences.	297

ADVERSE EFFECTS OF TMS

Potential TMS adverse effects include

- Seizures
- Syncope & presyncope
- Hearing changes (Tinnitus, hearing loss)
- Headaches; neck, scalp and dental pain
- Cognitive changes

SEIZURES AND TMS

Clinical Neurophysiology 130 (2019) 1409-1416



Contents lists available at ScienceDirect

Clinical Neurophysiology

journal homepage: www.elsevier.com/locate/clinph

Seizures from transcranial magnetic stimulation 2012–2016: Results of a survey of active laboratories and clinics



Adam J. Lerner^{a,*}, Eric M. Wassermann^b, Diana I. Tamir^{c,d}

^a Center for Bioethics, New York University, New York, NY 10003, USA

^b Behavioral Neurology Unit, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA

- ^c Department of Psychology, Princeton University, Princeton, NJ 08544, USA
- ^d Princeton Neuroscience Institute, Princeton University, Princeton, NJ 08544, USA

SEIZURE DETAILS

Table 2

Characteristics of reported seizures and subjects.

Seizure description	Frequency	Target	Diagnosis	Medications	Previous TMS
1. "Clinical seizure"	Single/Paired- pulse	Frontal cortex	Epilepsy	Valproate, zonisamide	None
2. Myoclonic	Single/paired- pulse	M1	Myoclonus epilepsy	Antiepileptic(s)	Some (unspecified)
3. Myoclonic	Single/paired- pulse	M1	Myoclonus epilepsy	Antiepileptic(s)	Some (unspecified)
4. Secondary generalized	Single-pulse	M1	Epilepsy	Topiramate, valproate, clobazam	None
5. Partial	Single-pulse	M1	Multiple sclerosis (possible)	None	None
6. Complex partial	Single-pulse	M1	None	None	1 session
7. Partial [†]	Single-pulse	M1	Tumor	Sertraline	2 sessions
<u>8. Partial[*]</u>	Single-pulse	M1	Tumor	Levitiracetam. lamotrigine	1 session
9. Partial	Single-pulse	M1	None	None	None
10. Secondary generalized	Single-pulse	IPS	None	Oral contraceptives	None
11. Generalized	Single-pulse	M1 (round coil at vertex)	Paraparesis	None	None
12. Generalized [*]	Single-pulse	M1	Epilepsy	Clobazam, pregabalin, zonisamide, levetiracetam, valproate, hydantoin	None
13. Not reported	Single pulse	M1	Stroke	Not reported	None
14. Partial	Single-pulse	M1	Arteriovenous malformation	None	None
15. Myoclonic	0.3 Hz	M1 (round coil at vertex)	Myoclonus epilepsy	Valproate, zonisamide, levetiracetam, clobazam	None
16. Generalized	1 Hz	DLPFC	Stroke	Atorvastatin, warfarin	None
17. Partial [*]	7 Hz	M1	Epilepsy	Valproate, eslicarbazepine, lacosamide, levetiracetam	None
18. Partial then generalized	10 Hz	M1	Stroke	Some (unspecified)	Some (Unspecified)
19. Secondary generalized	10 Hz	M1	Stroke	Trifluoperazine	None
20. Secondary generalized	15 Hz	DLPFC	Schizophrenia	Risperidone	4 sessions
21. Secondary generalized	18 Hz	DLPFC	Depression	None	7 sessions
22. Secondary generalized	18 Hz	DLPFC	Depression	None	12 sessions
			Alcoholism		
23. Generalized	18 Hz	DLPFC	Depression/rheumatoid arthritis	Methotrexate	Unreported
24. Secondary generalized	20 Hz	DLPFC	Depression	Mirtazepine	None
25. Secondary generalized	iTBS	M1	Stroke	None	None

SEIZURES ARE RARE!

318,560

24

Totals

19

57,185

.07/1000

Table 1 Seizures by TMS protocol and risk category.															
	Total Elevated subject risk El			Elevated protocol risk Elevated protocol & subject risk					No elevated risk						
TMS Protocol	Seizures	Sessions	Risk	Seizures	Sessions	Risk	Seizures	Sessions	Risk	Seizures	Sessions	Risk	Seizures	Sessions	Risk
Single/Paired-pulse	13	112,897	.12/1000	10	12,201	.82/1000							3	100,696	.03/1000
Low-frequency (rTMS \leq 1 Hz)	3	90,631	.03/1000	3	36,258	.08/1000							0	54,373	.00/1000
High-frequency (rTMS > 1 Hz)	4	82,588	.05/1000	3	5215	.58/1000	0	1029	.00/1000	1	163	6.13/1000	0	76,181	.00/1000
Intermittent Theta Burst	1	16,952	.06/1000	1	1813	.55/1000	0	7909	.00/1000	0	4501	.00/1000	0	2729	.00/1000
Continuous Theta Burst	0	8568	.00/1000	0	826	*	0	673	*	0	2075	.00/1000	0	4994	.00/1000
H-coil high-frequency rTMS	3	6924	.43/1000	2	872	2.29/1000	0	2948	.00/1000	0	10	*	1	3094	.32/1000

Number of sessions and seizures for different TMS protocols and subject and protocol risk categories. H-coil high-frequency stimulation data are listed separately from standard high-frequency (>1 Hz) data. With the exception of standard high-frequency (>1Hz) data, other numbers include round, figure-8, "double cone," and H-Coils. Three likely spontaneous seizures (#8, #12, and #17 in Table 3) are included. Seizure #7 is not included because the number of sessions was not reported. *No seizures reported; sample size < 1000 sessions.

.33/1000

.00/1000

1

6749


.15/1000

4

242,067

.02/1000

12,559



SOME NOTABLE FACTS

- Majority of seizures (62%) occurred on **first exposure** to TMS
- With the exception of patients with epilepsy, risk of seizures is very low even in otherwise "high-risk populations"
 - 19 seizures in 57,185 sessions = 0.33/1000
 - At least 8 of these 19 seizures occurred in patients with known epilepsy
- Seizure risk in patients with epilepsy is higher
 - Between 1.4% (Bae et al, 2007) and 2.9% (Pereira et al, 2016)
- Seizure risk may be higher using H-coil device

WHAT ABOUT WITH CLINICAL RTMS?

Brain Stimulation 14 (2021) 965-973



Contents lists available at ScienceDirect

Brain Stimulation

journal homepage: http://www.journals.elsevier.com/brain-stimulation

Seizure risk with repetitive TMS: Survey results from over a halfmillion treatment sessions



體

BRAIN

STIMULATIO

Joseph J. Taylor ^{a, b, *}, Noam G. Newberger ^c, Adam P. Stern ^{d, e}, Angela Phillips ^{f, g}, David Feifel ^{h, i}, Rebecca A. Betensky ^j, Daniel Z. Press ^{d, k}

SEIZURES AND CLINICAL RTMS

consistencies. In total, 18 seizures were reported in 586,656 sessions and 25,526 patients across all device manufacturers. The overall seizure rate was 0.31 (95% CI: 0.18, 0.48) per 10,000 sessions, and 0.71 (95% CI: 0.42, 1.11) per 1000 patients. The Brainsway H-coil seizure rate of 5.56 per 1000 patients (95% CI: 2.77,9.95) was significantly higher (p < 0.001) than the three most widely used figure- 8 coil devices' combined seizure rate of 0.14 per 1000 patients (95% CI: 0.01, 0.51).

Table 2

	Per 10,000 Sessions		Per 1000 Patients			
Manufacturer	Estimated Seizure Rate	95% CI	Estimated Seizure Rate	95% CI		
All	0.25	(0.14, 0.42)	0.61	(0.33, 1.02)		
Brainsway	1.56	(0.78, 2.80)	5.56	(2.77, 9.95)		
Magstim	0.00	(0.00, 0.51)	0.00	(0.00, 1.75)		
MagVenture	0.24	(0.03, 0.88)	0.73	(0.09, 2.62)		
Neuronetics	0.03	(0.00, 0.17)	0.06	(0.00, 0.35)		

Seizure rate by device. Seizure rates were estimated per 10,000 sessions and per 1000 patients across the four most widely used manufacturers.

SO WHAT CAN WE CONCLUDE?

Clinical Neurophysiology 130 (2019) 1397-1398



Contents lists available at ScienceDirect

Clinical Neurophysiology

journal homepage: www.elsevier.com/locate/clinph

Editorial

Seizures with TMS: Much ado about (almost) nothing?

See Article, pages 1409–1416



BUT you still need to be prepared!

WHAT ABOUT OTHER ADVERSE EFFECTS?

Syncope (Fainting) and presyncope

- True incidence is unknown, but several cases reported. Likely underreported as not as "serious" as seizure
- In study by Lerner et al, 29/174 responding facilities (17%) reported experiencing cases (often multiple) of syncope (much more than seizures)
- Risk factors can include orthostasis, prior history of syncope (including in response to blood draws), history of cardiac issues etc.
- Features suggesting syncopal origin included preceding presyncope / lightheadedness, diaphoresis, nausea; and very short post-event confusion
- Be aware of convulsive syncope as a differential for seizures!

HEARING CHANGES

- TMS is louder than it sounds!
 - Noise level of a single pulse has been reported to be between 125-140 dB! (Koponen 2020, Kukke 2017), but hard to measure using standard sound meters because pulse is so short
 - rTMS may be 95-115 dB (Koponen 2020), well above OSHA safety limits
- Permanent hearing threshold changes reported in one participant whose ear plug slipped out of one ear (Zangen 2005)
- Hearing protection critical (e.g. using 32dB noise-reducing earplugs)
 - No changes in hearing sensitivity after TMS when used (Pascual-Leone 1992, O'Reardon 2007)
- TMS technicians should wear earplugs too!
- Individuals with cochlear implants should NOT undergo TMS



HEADACHES AND MUSCULOSKELETAL PAIN

• The most common TMS side effect

- Studies in RCTs that systematically capture side effects have reported rates between 28% (Loo 2008) and 65% (Blumberger 2018), much higher than with sham stimulation (typically 10-20%)
- TMS stimulation itself can be painful, particularly to naïve patients
- Musculoskeletal and pain side effects vary greatly depending on location and orientation of stimulation (e.g. DLPFC >> M1)
 - With DLPFC, can get repetitive blinking, eye pain
 - In posterior regions, can get neck muscle and jaw activation
- Headaches typically respond well to OTC analgesics
- Local painfulness of prefrontal rTMS declines over first few days of treatment (Janicak 2008, Anderson 2009)

COGNITIVE CHANGES

- In patients undergoing experimental single-session studies, transient cognitive changes lasting only a few minutes typically reported
- Following rTMS course for TRD, no clear cognitive gains or cognitive side effects in systematic reviews (McClintock 2019, limori 2019)
- Possible "trends toward improvement in the neurocognitive profile" in patients undergoing rTMS for TRD (Serafina 2015)
 - May have some improvement in performance with the Trail Making Test (Martin 2017)
 - Patients with baseline cognitive dysfunction may have improvements in verbal memory associated with improvements in affective symptoms (Gregory 2022)
- Some patients can report transient lightheadedness / "brain fog" immediately at the end of a session, which improves within minutes

TASK PERFORMANCE CHANGES WITH RTMS

Hadra's C

Study	Year		Hedge's G (95% CI)	% Weight
Digit Span Forward				
Boggio et al.	2005		0.20 (-0.59, 0.99)	9.52
Holtzheimer et al.	2004		0.05 (-0.96, 1.07)	5.72
Loo et al.	2001		0.63 (-0.37, 1.63)	5.84
Loo et al.	2007		0.08 (-0.57, 0.74)	13.79
Mogg et al.	2008	•	0.00 (-0.51, 0.51)	22.61
Myczkowski et al.	2012		0.35 (-0.72, 1.42)	5.18
Nadeau et al.	2014		0.41 (-0.24, 1.06)	13.80
Wajdik et al.	2014		-0.46 (-0.96, 0.04)	
* Subtotal (Q = 6.872,	p = 0.442)	- \$	0.04 (-0.21, 0.28)	100.00
Digit Span Backwar				
Boggio et al.	2005		0.60 (-0.20, 1.40)	9.72
Holtzheimer et al.	2004		0.66 (-0.38, 1.70)	5.77
Loo et al.	2001		0.27 (-0.71, 1.26)	6.45
Loo et al.	2007		0.42 (-0.24, 1.08)	14.33
Mogg et al.	2008		-0.13 (-0.65, 0.38)	
Nadeau et al.	2014		0.43 (-0.22, 1.09)	14.62
Wajdik et al.	2014		-0.38 (-0.88, 0.12)	
* Subtotal (Q = 8.977,	p = 0.175)	\diamond	0.11 (-0.14, 0.36)	100.00
Digit Symbol Substi				
Avery et al.	1999		— 0.85 (-0.91, 2.62)	2.37
Holtzheimer et al.	2004		0.37 (-0.66, 1.39)	7.06
Mogg et al.	2008		-0.22 (-0.74, 0.29)	
Moser et al.	2002		0.66 (-0.27, 1.58)	8.64
Myczkowski et al.	2012		0.02 (-1.04, 1.08)	6.59
Nadeau et al. Wajdik et al.	2014 2014		0.38 (-0.27, 1.04)	17.17 30.01
			0.26 (-0.24, 0.75) 0.18 (-0.09, 0.46)	
Subtotal (Q = 4.641,	p = 0.591)	\sim	0.18 (-0.09, 0.40)	100.00
Stroop Colour	2005	-	0.07/0.40 4.40	0.74
Boggio et al.	2005		0.37 (-0.42, 1.16)	8.74
Hausmann et al.	2004		0.21 (-0.47, 0.88)	12.13
Holtzheimer et al.	2004		-0.92 (-1.99, 0.14)	
Huang et al. Moser et al.	2012 2002		0.62 (0.08, 1.16)	19.04 6.71
Moser et al. Mosimann et al.	2002		-0.22 (-1.12, 0.69)	7.66
Mosimann et al. Myczkowski et al.	2004		0.63 (-0.22, 1.48) 0.22 (-0.84, 1.28)	4.86
Myczkowski et al. Nadeau et al.	2012		-0.14 (-0.78, 0.50)	
Waidik et al.	2014		0.00 (-0.49, 0.49)	22.45
Subtotal (Q = 10.210		~	0.16 (-0.08, 0.39)	100.00
Subiotal (G = 10.210	p = 0.251)	\sim	0.10(-0.00, 0.39)	100.00

-3 -2.5 -2 -1.5 -1 -.5 0 .5 1 1.5 2 2.5 3

Study	Year	Hedge's G (95% Cl) % We	ight
COWAT Letter F	uency		_
Avery et al.	1999	0.26 (-1.44, 1.97) 1.	50
Boggio et al.	2005		98
Hausmann et al.	2003		69
Holtzheimer et al.			13
Jorge et al.	2004		10
Loo et al.	2004		43
Loo et al.	2001		43 51
Loo et al.	2003		0.07
McDonald et al.	2007		74
Moser et al.	2002		31
Mosimann et al.	2002		16
Nadeau et al.	2014		0.92
Sachdev et al.	2014		
	2017		78 7.67
Wajdik et al.			
* Subtotal (Q = 12	.305, p = 0.503)	0.11 (-0.10, 0.32) 10	00.00
COWAT Semant			
Hausmann et al.	2004		3.87
Loo et al.	2001		98
Loo et al.	2003		19
Loo et al.	2007		0.12
Myczkowski et al.			56
Wajdik et al.	2014		5.28
* Subtotal (Q = 3.6	i12, p = 0.606)	-0.09 (-0.39, 0.20) 10	00.00
Stroop Interferen			
Avery et al.	1999		.71
Boggio et al.	2005		.86
Hausmann et al.	2004		0.89
Holtzheimer et al.	2004		.83
Huang et al.	2012	-0.18 (-0.70, 0.35) 1	8.05
Moser et al.	2002	-0.96 (-1.91, -0.01) 5	.50
Mosimann et al.	2004	-0.12 (-0.95, 0.70) 7	.27
Myczkowski et al.	2012	0.28 (-0.78, 1.34) 4	.40
Nadeau et al.	2014		2.33
Spampinato et al.	2013	0.58 (-0.28, 1.44) 6	.78
Waidik et al.	2014	0.00 (-0.49, 0.49) 2	0.38
Subtotal (Q = 7.6	54, p = 0.663)	0.01 (-0.21, 0.23) 10	00.00
RAVLT Total (I -)	0		
Holtzheimer et al.		0.08 (-0.94, 1.09) 1	0.50
Loo et al.	2003		1.07
Loo et al.	2007		4.87
Myczkowski et al.	2012		.62
Waidik et al.	2014		3.95
* Subtotal (Q = 1.2			00.00
	<u> </u>	<u> </u>	
	-3 -2.5 -2 -1.5 -15 0 .5	1 1.5 2 2.5 3	

					neuge s o	
Study	Year				(95% CI)	% Weigh
Trail Making Test	A					
Avery et al.	1999				0.37 (-1.34, 2.08	1.66
Hausmann et al.	2004				-0.20 (-0.87, 0.4	
Holtzheimer et al.	2004				0.97 (-0.10, 2.04	
Huang et al.	2012				0.65 (0.11, 1.19)	
Loo et al.	2007	_			0.32 (-0.34, 0.98	
Moser et al	2002				0.45 (-0.47, 1.36	
Mosimann et al.	2004		-		0.73 (-0.12, 1.58	
Myczkowski et al.	2012				0.20 (-0.86, 1.27	
Nadeau et al.	2014		-		0.50 (-0.14, 1.14	
Wajdik et al.	2014				-0.14 (-0.63, 0.3	
Pal et al.	2010				-0.06 (-0.90, 0.7	
* Subtotal (Q = 10.			0		0.28 (0.06, 0.50)	
Trail Making Tes	B					
Avery et al.	1999				0.81 (-0.95, 2.57) 1.39
Boggio et al.	2005				0.10 (-0.68, 0.89	
Hausmann et al.	2004				0.00 (-0.67, 0.67	
Holtzheimer et al.	2004		T		1.27 (0.16, 2.38)	
Huang et al.	2012				0.81 (0.26, 1.35)	
Jorge et al.	2004		· · · · · · · · · · · · · · · · · · ·		0.03 (-0.84, 0.91) 5.60
Loo et al.	2007	-	•		0.37 (-0.29, 1.02	9.92
Moser et al.	2002				1.37 (0.37, 2.37)	4.30
Mosimann et al.	2004	_			0.60 (-0.24, 1.44) 6.05
Myczkowski et al.	2012				-0.26 (-1.33, 0.8	0) 3.81
Nadeau et al.	2014		•		0.11 (-0.52, 0.75) 10.79
Pal et al.	2010		<u> </u>		-0.07 (-0.91, 0.7	
Wajdik et al.	2014		+		-0.27 (-0.77, 0.2	
* Subtotal (Q = 19.	937. p = 0.068)		\diamond		0.26 (0.06, 0.47)	
			<u> </u>			
	0 05 0			5 0 05	2	
	-3 -2.5 -2	-1.5 -15	0.511	.5 2 2.5	3	

PREGNANCY

- No meaningful / physiologically relevant electric field at the level of the developing fetus (Yanamalda 2017)
- TMS has been used for treatment of depression during pregnancy, with no significant side effects
- Children born to mothers treated during pregnancy with rTMS for depression did not have increased perinatal complications or cognitive/motor developmental abnormalities (Kim 2019)
- Main risk is risk of maternal seizure (which is very low)

PEDIATRICS

- Zewdie 2020: Reviewed data from 384 children who received > 3.5 million stimulations at a single center (U of Calgary, Canada)
 - Included >500k stimulations with single- and paired-pulse TMS, and ~3 million stimulations with rTMS
 - No seizures (despite 221 participants having brain injuries or epilepsy)
 - Reported side effects to rTMS include HA (<17%), neck pain (<30%), tingling (<25%), presyncope / lightheadedness (<30%), and nausea (10%)
- Hong 2015: No major adverse effects in 76 children receiving TBS
 - HA 6.6%, tingling 2.6%
- Hearing protection again recommended, but no documented hearing changes

SEIZURES DURING TMS MAPPING

	Clinical Neurophysiology 137 (2022) 193–206	
	Contents lists available at ScienceDirect	4
	Clinical Neurophysiology	
ELSEVIER	journal homepage: www.elsevier.com/locate/clinph	

Image-guided TMS is safe in a predominately pediatric clinical population



Anneliesse A. Braden ^{a,b,c,*}, Sarah E. Weatherspoon ^{b,c}, Talitha Boardman ^{b,c}, Theresa Williard ^c, Abigail Adkins ^d, Savannah K. Gibbs ^c, James W. Wheless ^{b,c}, Shalini Narayana ^{a,b,c}

- TMS motor or language mapping carried out in 500 sessions (410 pediatric, 90 adult) in 429 patients. 399 sessions were in patients with dx of epilepsy
- 29 seizures occurred, 28 of which were in patients with epilepsy. Remaining 1 seizure occurred in patient with brain tumor
- Most common adverse event was transient pain at stimulation site

"SAFETY TABLES"

Rossi 2009

Table 4

Maximum safe duration (expressed in seconds) of single trains of rTMS. Safety defined as absence of seizure, spread of excitation or afterdischarge of EMG activity. Numbers preceded by > are longest duration tested. Consensus has been reached for this table.

Frequency (Hz)	Intensity (Intensity (% of MT)						
	90%	100%	110%	120%	130%			
1	>1800 ^a	>1800	>1800	>360	>50			
5	>10	>10	>10	>10	>10			
10	>5	>5	>5	4.2	2.9			
20	2.05	2.05	1.6	1.0	0.55			
25	1.28	1.28	0.84	0.4	0.24			

Table 5

Adapted from Table 4 (Part A) and Table 3 (part B) of Chen et al., 1997, with permission from the authors. Safety recommendations for inter-train intervals for 10 trains at <20 Hz. The maximum duration of pulses for individual rTMS trains at each stimulus intensity should not exceed those listed in the Part B of the table. A consensus has been reached in adopting this table at this point. However, there is a need to extend these investigations and provide more detailed guidelines that may apply also to non-motor areas.

Inter-train interval (ms)	Stimulus	intensity (% of MT)							
	100%		105%	110%			120%		
Part A 5000 1000 250	Safe Unsafe (EMG spread after 3 trains) Unsafe ^a			SafeSafeUnsafeaUnsafe (EMG spread after 2 trains)UnsafeaUnsafe (EMG spread after 2 trains)			Insufficient data Unsafe (EMG spread after 2 trains) Unsafe (EMG spread after 3 trains)		
Frequency (Hz)	100%		110%		120%		130%		
	Duration (s))/pulses	Duration (s)	Duration (s)/pulses Duration (s))/pulses Duration (s)/pulses		
Part B									
1	>270	>270	>270	>270	>180	>180	50	50	
5	10	50	10	50	10	50	10	50	
10	5	50	5	50	3.2	32	2.2	22	
20	1.5	30	1.2	24	0.8	16	0.4	8	
25	1.0	25	0.7	17	0.3	7	0.2	5	

^a These stimulus parameters are considered unsafe because adverse events occurred with stimulation of lower intensity or longer inter-train interval, but no adverse effects were observed with these parameters.

BUT REMOVED IN 2021!

Despite such variety, as reviewed for these guidelines, neither seizure occurrence nor other AEs emerged consistently, thus indicating that whatever the protocol of intervention, the technique can be considered basically safe. Therefore, we have decided not to provide a formal update of the previous safety tables, and that, instead, we propose "operational guidelines". Clearly, the parameters of stimulation used for MST should not be exceeded. The usual lowest parameters of stimulation to induce seizures during MST are 100% of maximal stimulator output (at least for these commercially available devices), frequency of 25 Hz, delivered in a single train lasting up to 10 s. Therefore, every combination of inten-



Recommendations: we propose that in all clinical trials and scientific studies that use conventional rTMS protocols, the Principal Investigator (PI) has to: (i) balance the overall risk/benefit ratio of the proposed intervention, (ii) use neurophysiological monitoring (i.e., emergence of motor twitches during stimulation) as a warning for increased cortical excitation, in case the combination of parameters of stimulation exceeds the 2009 safety guidelines, (iii) reconsider the protocol of the trial if a seizure occurs under these circumstances, and iv) alert the scientific community through dedicated scientific Journals about the new possibly unsafe combination nations of parameters.

WHAT ABOUT OTHER DEVICES

MRI

- Conventional TMS coils and systems are NOT MRIcompatible
- Special MRI-compatible coils are available, restricted to 3T or less scanners

IMPLANTED DEVICES

- TMS pulses delivered >10 cm from implanted pulse generator (IPG) have minimal effective electric field
 - Kuhn 2004: TMS at 2-10 cm from IPG caused malfunction. TMS < 2cm caused permanent damage
 - Considered safe in patients with pacemakers, ICDs
 - We delivered rTMS in patient with ventricular assist device without any complications
- TMS is safe in patients with Vagal Nerve Stimulation (VNS) devices providing stimulation is not applied to the neck

INTRACRANIAL IMPLANTS

- TMS causes minimal heating / displacement of titanium plates / rods / clips
- TMS is NOT safe in patients with cochlear implants
- In patients with DBS, TMS may be not safe if
 - < 10 cm from IPG
 - OR TMS is close to lead, there are loops in the electrode wires under the coil, and high TMS pulses are used (Phielipp 2017)
- Recent work suggests that TMS may be safe in patients with implanted stereotactic EEG electrodes for epilepsy monitoring (Wang 2022 Bioarxiv)

SUMMARY

- TMS is generally safe and very well-tolerated
- The most common side effects are musculoskeletal pain and headache
- Seizures are very rare outside of patients with epilepsy
- TMS can be performed in patients with implanted devices, provided safety guidelines are adhered to